Biogen 4th-qtr beats expectations

29 January 2019
biogen-big-1

US biotech Biogen (Nasdaq: BIIB) today posted full-year and fourth-quarter financial results for 2018. Full year total revenues were $13.5 billion, a 10% increase versus the prior year.

Full year GAAP net income and diluted earnings per share (EPS) attributable to Biogen Inc. were $4.4 billion and $21.58, respectively, compared to $2.5 billion and $11.92, respectively, in the prior year.

For the fourth-quarter, total revenue increased 6.6% to $3.53 billion, exceeding consensus estimates of $3.40 billion. Net income attributable to Biogen was $946.8 million, or $4.73 per share, for the three months, compared with a net loss of $297.4 million, or $1.40 per share, a year earlier. Adjusted EPS was $6.99 a share, beating the FactSet consensus of $6.73 a share.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology